Replies to post #89849 on Biotech Values

[DewDiligence]

MNTA: According to a Form 13G filed today, T Rowe Price increased its holding by 52K shares (from 4,468,373 to 4,520,273) during November and December. I will update the table in #msg-46074498 when all of the Form 13G’s for the period ending 12/31/09 have been filed.

[DewDiligence]

MNTA Major Shareholders

[Updated for SEC filings through 2/17/10.]


The table below shows all shareholders with a 5% stake
on an SEC reporting basis and all insiders with a 1% stake.
Insider holdings are accurate as of today and include restricted
stock and options, whether or not vested. Non-insider holdings
other than Novartis are as of 12/31/09 unless otherwise indicated
in the table footnotes. (Novartis’ holding is accurate as of today
because NVS is a 10% holder on an SEC reporting basis and
it has the same reporting requirements as an insider.)

The percentages shown below are based on 49.1M diluted
shares for valuation purposes (#msg-42163809), and hence
they differ from the percentages reported in SEC filings.

 
                             Shares  Stake 
 Novartis                  4,708,679  9.6% 
 T Rowe Price              4,520,273  9.2% 
 BlackRock Inc.            2,782,260  5.7% 
 Visium Asset Mgmt         2,307,096† 4.7% 
 Samana Capital            2,048,303  4.2% 
 Craig Wheeler (CEO)         987,344  2.0% 
 Alan  Crane (Director)      652,202  1.3% 
 G. Venkataraman (SVP, R&D)  628,540  1.2%  
 Ram Sasisekharan (Director) 492,344  1.0%  
  
 †As of  1/22/10 (from 13G filing  1/29/09).